GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » E10

Lexaria Bioscience (Lexaria Bioscience) E10 : $0.00 (As of Feb. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2024 was $0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Feb. 2024.

During the past 3 years, the average E10 Growth Rate was -4.10% per year. During the past 5 years, the average E10 Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lexaria Bioscience was 18.10% per year. The lowest was -4.10% per year. And the median was -0.50% per year.

As of today (2024-06-15), Lexaria Bioscience's current stock price is $1.38. Lexaria Bioscience's E10 for the quarter that ended in Feb. 2024 was $0.00. Lexaria Bioscience's Shiller PE Ratio of today is .


Lexaria Bioscience E10 Historical Data

The historical data trend for Lexaria Bioscience's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience E10 Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexaria Bioscience's E10

For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.



Lexaria Bioscience E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0/125.4675*125.4675
=0.000

Current CPI (Feb. 2024) = 125.4675.

Lexaria Bioscience Quarterly Data

per share eps CPI Adj_EPS
201404 0.000 98.920 0.000
201407 0.000 99.315 0.000
201411 0.000 99.078 0.000
201502 0.000 99.078 0.000
201505 0.000 100.263 0.000
201508 0.000 100.579 0.000
201511 0.000 100.421 0.000
201602 0.000 100.421 0.000
201605 0.000 101.765 0.000
201608 0.000 101.686 0.000
201611 0.000 101.607 0.000
201702 0.000 102.476 0.000
201705 0.000 103.108 0.000
201708 0.000 103.108 0.000
201711 0.000 103.740 0.000
201802 0.000 104.688 0.000
201805 0.000 105.399 0.000
201808 0.000 106.031 0.000
201811 0.000 105.478 0.000
201902 0.000 106.268 0.000
201905 0.000 107.927 0.000
201908 0.000 108.085 0.000
201911 0.000 107.769 0.000
202002 0.000 108.559 0.000
202005 0.000 107.532 0.000
202008 0.000 108.243 0.000
202011 0.000 108.796 0.000
202102 0.000 109.745 0.000
202105 0.000 111.404 0.000
202108 0.000 112.668 0.000
202111 0.000 113.932 0.000
202202 0.000 115.986 0.000
202205 0.000 120.016 0.000
202208 0.000 120.569 0.000
202211 0.000 121.675 0.000
202302 0.000 122.070 0.000
202305 0.000 124.045 0.000
202308 0.000 125.389 0.000
202311 0.000 125.468 0.000
202402 0.000 125.468 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Lexaria Bioscience  (NAS:LEXXW) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lexaria Bioscience E10 Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Traded in Other Exchanges
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.